Prot# EOP1004C: Phz 2/3 Rndmzd, Dbl-Masked, Cntrld, Dose-Ranging, Mltctr Comparative Trial in Prl'l Groups to Establish Safety & Efficacy of Intravitreal Injections of EYE001 (Anti-VEGF Pegylated Aptamer) Given Every 6 Wks for 54 Wks in Patients w/ Exudat

Project: Research project

Project Details

StatusFinished
Effective start/end date12/20/0110/16/07

Funding

  • Eyetech Pharmaceuticals, Inc. (EOP1004C)